Global Liquid Biopsy Market 2022-2028

May 2022 | 88 pages | ID: GEDAA6B4342CEN
Gen Consulting Company

Abstracts

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. The market for liquid biopsy worldwide is expected to reach USD 11,120 million by 2028, recording a CAGR of 16.1% over the forecast period as per the latest report by Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global liquid biopsy market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the liquid biopsy industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the therapy, application, biomarker type, technology, and region. The global market for liquid biopsy can be segmented by therapy: oncology, noninvasive prenatal testing (NIPT), others (e.g. organ transplant). The NIPT segment is estimated to account for the largest share of the global liquid biopsy market. Liquid biopsy market is further segmented by application: diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest revenue share in 2021. Based on biomarker type, the liquid biopsy market is segmented into: cell-free nucleic acids, circulating tumor cells, others. Globally, the cell-free nucleic acids segment made up the largest share of the liquid biopsy market. On the basis of technology, the liquid biopsy market also can be divided into: next-generation sequencing (NGS), polymerase chain reaction (PCR), others. The next-generation sequencing (NGS) segment was the largest contributor to the global liquid biopsy market in 2021. Liquid biopsy market by region is categorized into: Asia Pacific, Europe, North America, Rest of the World (RoW).

By therapy:

• oncology
• noninvasive prenatal testing (NIPT)
• others (e.g. organ transplant)

By application:

• diagnosis
• early detection/screening
• monitoring
• therapy guidance

By biomarker type:

• cell-free nucleic acids
• circulating tumor cells
• others

By technology:

• next-generation sequencing (NGS)
• polymerase chain reaction (PCR)
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The market research report covers the analysis of key stake holders of the global liquid biopsy market. Some of the leading players profiled in the report include Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co., Ltd., Becton, Dickinson and Company, Berry Genomics Co., Ltd., BGI Group, Biocartis Group, Biocept, Inc., Biodesix, Inc., Biolidics Limited, Bio-Rad Laboratories, Inc., Bio-Techne Corp., CareDx, Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina, Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics, Inc., NeoGenomics Laboratories, Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California, Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global liquid biopsy market.
• To classify and forecast the global liquid biopsy market based on therapy, application, biomarker type, technology, region.
• To identify drivers and challenges for the global liquid biopsy market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global liquid biopsy market.
• To identify and analyze the profile of leading players operating in the global liquid biopsy market.

Why Choose This Report

• Gain a reliable outlook of the global liquid biopsy market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY THERAPY

Oncology
Noninvasive prenatal testing (NIPT)
Others (e.g. organ transplant)

PART 6. MARKET BREAKDOWN BY APPLICATION

Diagnosis
Early detection/screening
Monitoring
Therapy guidance

PART 7. MARKET BREAKDOWN BY BIOMARKER TYPE

Cell-free nucleic acids
Circulating tumor cells
Others

PART 8. MARKET BREAKDOWN BY TECHNOLOGY

Next-generation sequencing (NGS)
Polymerase chain reaction (PCR)
Others

PART 9. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 10. KEY COMPANIES

Adaptive Biotechnologies Corp.
Agilent Technologies Inc.
Amoy Diagnostics Co., Ltd.
Becton, Dickinson and Company
Berry Genomics Co., Ltd.
BGI Group
Biocartis Group
Biocept, Inc.
Biodesix, Inc.
Biolidics Limited
Bio-Rad Laboratories, Inc.
Bio-Techne Corp.
CareDx, Inc.
Danaher Corp.
Eurofins Scientific
EXACT Sciences Corporation
Illumina, Inc.
Koninklijke Philips N.V.
Merck KGaA
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
OncoCyte Corporation
Oxford Nanopore Technologies Limited
Pacific Biosciences of California, Inc.
Qiagen N.V.
Roche Holding AG
Takara Bio Inc.
Thermo Fisher Scientific Inc.
VolitionRx Limited
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER